Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Nike Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Nike Inc trades at $35.11 (market cap $52.48B). The key difference: Nike Inc is the larger of the two by market cap, and Nike Inc pays the higher dividend (4.64%). Which is the better fit depends on your goals.
| GEHC | NKE | |
|---|---|---|
Market Cap | $31.07B | $52.48B |
Volume | 3,443,020 | 30,189,626 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $69.68 |
52-Week Low | $59.48 | $33.87 |
Enterprise Value | $39.53B | $55.18B |
Dividend Yield | 0.23% | 4.64% |
Typical Hold Time | — | 155 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Nike (NKE) trades at $35.35, up 1.84% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from declining revenue ($46.31B in 2025 vs. $51.4B in 2024) and compressed margins (net margin 6.74%), though valuation appears reasonable with P/E of 16.9. Analyst consensus remains mixed with 47% buy ratings but a $36.80 price target suggesting limited upside. Recent news highlights inventory challenges and China market pressures.
Nike's turnaround strategy focuses on inventory discipline and digital DTC growth, but execution risks persist amid weak consumer demand. The stock offers moderate value at current levels with dividend support, though revenue stabilization is critical for sustained recovery. Near-term catalysts include Q4 2026 earnings on June 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
